July 27, 2015

In a move that will reshape the generic pharmaceuticals landscape, Teva announced Monday that it would be acquiring Allergan Generics for $40.5 billion. 

July 24, 2015

On Friday, Stichting Preferred Shares Mylan, an independent foundation established in the Netherlands, announced that it would exercise its full call option to purchase 488,388,431 preferred shares in Mylan.

July 15, 2015

A collection of eight consumer groups have written to Federal Trade Commission chair Edith Ramirez in opposition of the ongoing potential merger between pharmaceutical companies Teva and Mylan. 

July 14, 2015

Both Mylan and Dr. Reddy’s Laboratories have announced the launch of their generic version of dementia drug Namenda.

July 9, 2015

 Mylan announced Thursday that it had launched its generic version of Valeant’s Targretin (bexarotene) 75-mg capsules.

June 19, 2015

The move gives Teva standing in Dutch court, should they decide to pursue action against Mylan.

June 16, 2015

Mylan’s largest shareholder has promised to back the company’s bid to buy Perrigo, which would help fend off Teva’s $40 billion takeover offer.

June 3, 2015

Mylan announced on Tuesday that it had launched its generic version of Teva’s  Seasonique birth control.

May 26, 2015

Acquisition target Perrigo recently filed a complaint to Irish Takeover Panel regarding Mylan proposal. 

May 20, 2015

Mergers and acquisitions among pharmaceutical companies has kicked into high gear this year, mirroring the larger trend sweeping across the entire spectrum of the health care industry since the implementation of the Affordable Care Act two years ago.

April 24, 2015

Mylan has announced that it will commence with a formal offer to acquire generic drug maker Perrigo.

April 22, 2015

Perrigo on Tuesday rejected a proposed acquisition by Mylan. 

April 22, 2015

Following Perrigo's rejection of a Mylan offer, Teva moves forward with its proposed acquistion of Mylan. 

April 21, 2015

Teva Pharmaceutical on Tuesday made a move for Mylan in a $40 billion deal barring Mylan's proposed acquisition of Perrigo. 

April 8, 2015

Mylan on Wednesday announced a proposal to acquire Perrigo in $29 billion deal. 

April 7, 2015

Mylan on Tuesday announced the launch of norethindrone and ethinyl estradiol tablets (chewable) 0.8 mg/0.025 mg and ferrous fumarate tablets, 75 mg (chewable).

March 11, 2015

Mylan launched its fentanyl transdermal system in 37.5-, 62.5- and 87.50-mcg/hr dosage strengths in the United States.

March 11, 2015

Mylan on Wednesday announced the launch of disulfiram tablets USP in dosage strengths of 250 mg and 500 mg.

March 11, 2015

Mylan expanded its portfolio of generic products with the U.S. launch of buprenorphine hydrochloride sublingual tablets in 2-mg and 8-mg strengths, the generic version of Subutex from Reckitt Benckiser.

March 2, 2015

Mylan on Friday announced the successful completion of the acquisition of Abbott Laboratories' non-U.S. developed markets specialty and branded generics business.

February 24, 2015

Mylan has been appointed as the exclusive India distributor of Sovaldi (sofosbuvir 400mg tablets) and Harvoni (ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, by Gilead Sciences. 

February 9, 2015

Mylan Inc. and its subsidiary Mylan Pharmaceuticals are being sued by Bayer Healthcare, Bayer Healthcare Pharmaceuticals and Onyx Pharamceuticals in relation to the filing of an abbreviated new drug application for sorafenib tablets, the generic version of Nexavar. 

 

February 2, 2015

Mylan announced that it will acquire certain businesses from specialty women's healthcare company Famy Care Limited for $750 million, with additional contingent payments of up to $50 million. 

January 15, 2015

Mylan on Thursday announced the launch of lamivudine tablets, 100 mg, the generic version of Epivir-HBV from GlaxoSmithKline.